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Genomic Analysis in Nephrology -
towards Systems Biology and Systematic Medicine?
Abstract
With the advent of transcriptome profiling techniques, an enormous amount of data has been generated
in the field of molecular nephrology. We will review analysis tools and challenges for genomic
approaches and present their application in gene-expression studies on kidney biopsies. The findings in
this rapidly evolving field may ultimately complement histopathological analysis, the current diagnostic
and prognostic gold standard. Altogether, genomics may bring nephrology one-step closer to a
systematic understanding of biological processes involved in renal disease.
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Abstract 
English: 
With the advent of transcriptome profiling techniques an enormous amount of data 
has been generated in the field of molecular nephrology. We will review analysis 
tools and challenges for genomic approaches and present their application in gene 
expression studies on kidney biopsies. The findings in this rapidly evolving field may 
ultimately complement histopathological analysis, the current diagnostic and 
prognostic gold standard. Altogether genomics may bring nephrology one step closer 
to a systematic understanding of biological processes involved in renal disease. 
 
French: 
Depuis l’introduction des techniques pour l’étude du profil du transcriptome beaucoup 
de données ont été créées dans ce domaine de la néphrologie moléculaire. Nous 
allons présenter et résumer les méthodes d’approches génomiques (par exemple 
puces ADN et bioinformatique) et les études récentes sur les biopsies rénales. Les 
résultats obtenus par les expériences dans ce secteur scientifique en pleine 
évolution pourraient compléter l’analyse classique histopathologique, comme source 
supplémentaire pour les diagnostiques moléculaires fondés sur les méthodes 
conventionnelles. 
En résumé, la génomatique permettrait aux néphrologues d’aller plus loin dans la 
compréhension systématique des processus biologiques. 
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1. Introduction 
In nephrology therapeutic decisions are often based on histopathological results of 
renal biopsies. But kidney biopsies still offer limited predictive strength and 
therapeutic consequence, e.g. in the nephrotic syndrome [1]. As correlation of 
histopathologic features with kidney function, e.g. creatinine clearance and outcome, 
is not always sufficient [2], additional sources for diagnostic information are desirable. 
In haematology and oncology gene expression analysis has added important 
information to routine diagnostic strategies. This has led to the implementation of 
gene expression in the state-of-the-art workup of specific diagnostic samples [3]. 
With sequencing of the human genome intriguing opportunities in clinical and 
experimental nephrology arise. It is now possible to analyse the transcriptome, i.e. 
tens of thousands of mRNAs expressed in a given tissue at a specific time. These 
genomic data have led together with similar –omic approaches (e.g. proteomics) to 
the development of systems biology, which aims to decipher on a global level the 
biological networks activated in health and disease.  
Gene expression analysis on renal tissue of diseased humans may allow the 
nephrology community to address two main topics: 
1. “How can we increase the impact of information we get from a renal biopsy 
(e.g. disease categories, response to therapy, patient outcome)?”  
2. “What are interconnected biological pathways activated in the respective 
clinical setting?” 
Altogether this may lead to more specific diagnoses, individualised therapies and a 
better understanding of renal disease (see figure 1). In this review we want to present 
selected gene expression studies performed on human renal tissue. All of these 
studies have laid the path to the above aims. 
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2. Tools in genomic nephrology 
Three methods used in modern gene expression profiling deserve special 
consideration: Real-time reverse transcription polymerase chain reaction (rt-RT-
PCR), microarrays and serial analysis of gene expression (SAGE). 
 
2.1. RT-PCR 
Real time-RT-PCR is an ultra-sensitive technique, which allows to rapidly quantify 
minute amounts of target mRNAs by determining the number of amplicons after each 
PCR cycle. With this approach it is possible to quantify mRNA expression from single 
glomeruli and even single cells, e.g. podocytes [4]. 
Expression levels of the molecule of interest have to be related to the amount of 
tissue analysed. This obstacle can be overcome by using several reference RNAs in 
parallel. These should have stable expression levels and are referred to as reference 
genes or housekeepers [5]. 
 
2.2. Microarrays 
While a major shortcoming of RT-PCR studies is the limited number of genes that 
can be examined, microarrays allow us to study the expression of several thousands 
of genes in one reaction. A microarray is a matrix of thousands of molecules (for 
gene expression studies oligonucleotides or cDNA probes) imprinted on a solid 
support. Labelled mRNA/cDNA from the tissue of interest hybridises to its 
complement sequence on the array. Measuring signal intensity allows quantification 
of mRNA abundance. The hallmark of the microarray experiment is the expression 
profile, i.e. the sample’s pattern of gene expression. A major limitation is the 
requirement of significant amounts of high quality mRNA as starting material. mRNA 
amplification before microarray analysis is an option but concerns have been raised 
about amplification bias. 
Microarrays have proven to be an excellent vehicle to gather expression data and 
create hypotheses [4, 6, 7]. 
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2.3. Serial Analysis of Gene Expression (SAGE) 
A third approach, SAGE (serial analysis of gene expression), was developed based 
on the experience from large-scale sequencing projects. In SAGE base pair 
sequence tags corresponding to unique mRNAs are sequenced in a tandem-ligated 
form. In a second step they are compared with a genomic database. Using SAGE 
thousands of mRNA SAGE tags can be studied. Thus, like microarrays, SAGE can 
provide a quantitative profile of expressed genes [8]. 
 
3. Challenges 
A number of obstacles have to be overcome for gene expression analysis of renal 
diseases: 
 
3.1. Addressing the complex architecture of the kidney 
Unlike the monoclonal neoplastic tissue used in the pioneering studies in 
haematology, the kidney is characterised by a high level of cellular heterogeneity. 
Three genomic studies on physiologic human kidneys revealed a high degree of 
compartmentalisation. Each compartment showed unique, reproducible and highly 
distinctive expression patterns. These genetic patterns correlate very well with 
different physiologic functions attributed to a given part of the kidney [9, 10]. Using 
SAGE Chabardès-Garonne et al. were able to study nephron-segment-specific gene 
expression patterns [11] and Takemoto et al. established a comprehensive 
glomerular expression profile of the mouse by advanced molecular and bioinformatic 
techniques [12]. 
Thus, when studying a given condition it is preferable to focus on a certain 
compartment rather than using whole renal lysates. This can be achieved by manual 
or laser microdissection techniques [13, 14]. It should also be noted that after 
screening for changes in mRNA expression these can be further localised to specific 
glomerular or tubulo-interstitial renal cells or even cell compartments by using 
conventional methods, e.g. immunohistochemistry or cell culture experiments. Such 
approaches may be completed in the future by advanced imaging methods, e. g. 
intravital 2-photon microscopy [15]. 
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3.2. Focal nature of kidney disease 
Along with the limited amount of tissue obtained by a fine needle biopsy, patchy 
patterns of potentially multi-staged lesions may result in considerable sample bias 
[4]. 
 
3.3. Clinical and molecular heterogeneity 
In nephrology the clinician faces a significant heterogeneity in confounding factors 
(e.g. diabetes, hypertension) and in the renal disease per se (subgroups of the same 
disease, e.g. WHO stages I to V in Lupus Nephritis). Thus, it is a challenge to create 
statistically sufficient patient cohorts for a reliable and valid study even of a common 
disease.  
To further complicate matters there may be pathogenetic heterogeneity within a 
disease entity and different diseases can show similar histopathologies (e.g. 
glomerulosclerosis). One of the best approaches to overcome the clinical and 
molecular heterogeneity is to create large enough patient cohorts for statistically 
feasible subgroup analysis. 
 
3.4. Bioinformatics 
In order to deal with the vast and often puzzling datasets obtained in microarray 
experiments a thorough bioinformatic workup is crucial. Using the software tools of 
cluster analysis, so called dendrograms can be created whose tree structure 
hierarchically visualises groups of samples with similar expression patterns [16]. 
Computer-aided interconnection of expression profiles with libraries of biological 
processes and molecular functions guides towards the application of systems 
biology, integrating data sets into their functional context. 
 
3.5. From genes to proteins 
It is important to realise that besides mRNA abundance there are other ways to 
influence biological processes: splicing of RNA, posttranslational modification of 
proteins and protein interaction. Thus, expression results on gene level have to be 
confirmed on protein level and if possible linked with gene function and activity. In 
complex human tissues available means are limited and immunohistochemistry is the 
most widely used approach.  
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4. Multi-centre renal gene expression study in Europe 
The logistic and biological issues mentioned above can best be addressed in a multi-
centre setting. To this end the European Renal cDNA Bank – Kroener-Fresenius 
Biopsy Bank (ERCB-KFB) was initiated in 1998. More than 20 European nephrology 
departments and nephro-pathologists have joined in a cooperation to study gene 
expression and follow a protocol for high throughput application of gene expression 
analysis of renal biopsies: After informed consent a minor part of a routine biopsy 
core is transferred to a pre-coded vial filled with RNase inhibitor (RNA later, Ambion). 
The biopsy specimens are shipped on cool packs together with anonymous clinical 
data sheets and histology reports to the core facility. Here glomeruli and tubulo-
interstitium are manually microdissected and mRNA is isolated from these dissected 
compartments. Gene expression analysis is performed by both real-time RT-PCR 
and microarrays (Fig. 2) [13]. A second protocol for RT-PCR analyses on 
formaldehyde fixed-paraffin embedded archival tissue made retrospective molecular 
studies on routine renal biopsies possible [14]. 
 
5. mRNA analysis of candidate genes in native renal biopsies 
In the following we will give some examples of successful gene expression studies in 
nephrology. This summary is by far not complete and very interesting studies remain 
unmentioned. 
 
5.1. Glomerulosclerosis- a final common pathway 
Many different renal diseases eventually lead to the same histopathologic pattern: 
glomerulosclerosis. In a pioneering study on renal gene expression Esposito et al. 
[17] shed light on the dysregulated composition of the underlying collagen synthesis. 
 
5.2. Building bridges between genes and clinical data 
In a proof of principle study on hydronephrotic kidneys Henger et al. [18] categorised 
renal lesions using a molecular, gene expression-based approach. They found a 
correlation between gene expression fingerprint and prognosis. In the field of 
translational research Schmid et al. [19] were able to distinguish focal segmental 
glomerulosclerosis and minimal change disease by glomerular gene expression. 
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5.3. Membranous Glomerulonephropathy (MGN) 
Formation of subepithelial immune complexes in MGN results in changes in the 
glomerular filtration barrier. In an „oeuvre-clé“ in molecular nephrology neutral 
endopeptidase (NEP) was identified as the first known human glomerular antigen in a 
specific clinical subgroup of MGN [20, 21]. Cohen et al. [22] found a significantly 
higher CD20 mRNA expression in MGN, which points towards a role of immigrating B 
cells in this disease. Thus, B cell targeted therapies, e.g. Rituximab, may be 
employed in a selective manner [23]. 
 
5.4. Lupus Nephritis (LN) 
LN has been extensively studied in animal models. Fewer studies have evaluated 
molecular mechanisms in human LN. Using microarray technology on human 
glomeruli Peterson et al. [24] demonstrated that B cells, different myelomonocytic 
lineages, expression of type I interferon inducible genes and cell proliferation are 
involved in LN. 
 
5.5. Rapidly Progressive Glomerulonephritis (RPGN) 
RPGN can be caused by completely different and incompletely understood 
mechanisms. Recently Ding et al. [25] could identify the loss of von Hippel-Lindau 
antigen (VHL) as one potential mechanism, which leads to up-regulation of hypoxia-
related genes. Blocking one of these genes, chemokine receptor CXCR4, proved to 
be an attractive therapeutic option in a rodent model. 
 
5.6. Diabetic Nephropathy (DN) 
DN represents the leading cause of end-stage renal disease in the industrialised 
world. Paradoxically, little is known about its molecular mechanisms. 
Baelde et al. [26] and Lindenmeyer et al. [27] could show by two independent 
expression studies that unlike in animal models vascular endothelial growth factor A 
(VEGF-A) is down-regulated in human DN. This may contribute to vascular 
rarefaction, tubulointerstitial fibrosis and thus progression towards end-stage renal 
disease.  
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6. Molecular approaches to renal transplant recipients 
 
6.1. Post-ischaemic renal failure 
A significant number of cadaveric renal transplant recipients develop post-ischaemic 
acute renal failure, which is known to influence long-term graft outcome. Using a 
microarray-based approach on cadaveric donor kidneys Hauser et al. [28] and Kainz 
et al. [29] identified an up-regulation of proinflammatory pathways as potential 
predictors of post-ischaemic renal failure and one-year allograft function, 
respectively. 
 
6.2. Chronic transplant failure 
While many acute immune-mediated rejection episodes can be treated effectively, 
chronic allograft nephropathy still represents a major challenge in renal 
transplantation. 
Correlating expression levels of genes significantly regulated in acute rejection with 
clinical follow up, Eikmans et al. [30, 31] found that up-regulation of certain genes 
(e.g. S100A8/9, TGFbeta) may predict a lower risk of developing chronic graft failure. 
High expression of Surfactant Protein-C, a protein originally known to be involved in 
alveolar stability [30], and high expression of B cell clusters, e.g. CD20 [32], may 
predict a rather unfavourable course. 
 
6.3. Addressing calcineurin inhibitor associated toxicity 
It is crucial but difficult in the current clinical setting to differentiate between chronic 
graft dysfunction and toxicity of calcineurin inhibitors. Studying expression levels of 
candidate genes, e.g. TGFbeta and laminin, may provide additional molecular 
information to guide clinical therapy [33, 34]. 
 
All the studies listed above show promising results and most have validated their 
results by additional means such as RT-PCR or immunohistology. However, reliabilty 
and validity of positive findings are further increased if confirmational data from 
independent patient cohorts are available. Therefore large-scale biobanks will be 
important not only for initial analyses but also for confirmatory studies. 
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7. Towards Systems biology  
Systems biology builds networks of interacting biological elements, e.g. genes, to 
help understand the function of the whole organism, using information from a wide 
variety of disciplines. Thus, systems biology has been described as the search for 
the syntax of biological information [35]. Three studies tried to integrate such 
syntactic approaches to decipher biological processes involved in renal disease. 
Computer-based gene promoter analysis helped in all three studies to better 
understand renal gene expression data. Kainz et al. [36] used for the first time 
computer-based promoter analysis to search for common promoter characteristics for 
co-regulated genes. They found similarities in transcription factor binding site motifs 
in genes commonly regulated in transplant organs. Schmid, Boucherot, Yasuda et al. 
[37] could show that a master inflammatory pathway is activated in progressive 
diabetic nephropathy. By analysing array data from DN the induction of NFkappa B 
(NFkB) target genes was over-represented. Futher computer-assisted promoter 
analysis deciphered the specific relevance of the transcription factor binding sites for 
NFkB and interferon regulatory factor in progressive disease. Cohen et al. [38] 
managed to characterise shared promoter structures of molecules linked to the 
unique functional unit of the glomerular slit diaphragm by applying state-of-the-art 
promoter modelling tools. Cadherin 5, a gene previously unrecognised in this context, 
along with nephrin and ZO-1 were found to share specific transcription factor binding 
sites in their respective promoter region. All three genes were also found to be co-
expressed and -regulated in different human glomerular diseases. 
Of note, the chances and opportunities brought about by systems biology extend far 
beyond promoter analysis. The multidimensional and comprehensive approach of 
systems biology, including also proteomics, computer science, mathematical 
modelling and others, will crucially contribute to the success of many future projects 
in molecular renal research. 
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8. Conclusion: on the eve of the “âge d’or” in nephrology? 
In this review, we could point out some of the many promising developments and 
exciting options, which are opening new avenues towards a systematic 
understanding of renal disease. This more comprehensive approach to renal disease 
may help us to establish a more systematic, mechanism-based medicine with 
individually tailoured therapies. And it may also help to better understand the 
biological systems involved in renal disease. 
Focusing the power of molecular analysis on the kidney has provided a few 
answers– and given raise to many new questions.
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Figure legends: 
 
Figure 1: Schematic overview of genomic approaches in medicine 
Clinical data (e.g. histological diagnosis, specific lab values) are correlated with 
genomic data (e.g. microarray). Regulation of specific genes is confirmed by other 
means (RT-PCR, immunohistochemistry). To understand the role of the regulated 
genes further experiments are needed in vitro and in vivo. At the end, a more 
comprehensive understanding of the biological processes can be achieved (here 
symbolized by a network). This may lead to the development of modern therapies or 
to the generation of more specific diagnosis criteria. 
 
Figure 2: The European Renal cDNA Bank – Kroener-Fresenius Biopsy Bank 
A small part of a renal biopsy is transferred to RNase inhibitor. Glomeruli and tubulo-
interstitium are manually microdissected at the core facility of the study. Expression 
analysis can be performed by real-time RT-PCR or microarrays. These data can be 
correlated with histology and clinical data.  
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